MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth SymptomBenzinga • 12/07/21
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced XerostomiaGlobeNewsWire • 12/07/21
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene RegulationGlobeNewsWire • 11/29/21
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/21
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q3 Earnings Expected to DeclineZacks Investment Research • 10/28/21
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis PigmentosaGlobeNewsWire • 09/09/21
MeiraGTx Holdings PLC (MGTX) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/29/21
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/21
MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing SummitGlobeNewsWire • 04/19/21
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to DeclineZacks Investment Research • 03/03/21
Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing TidePRNewsWire • 02/23/21
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced XerostomiaGlobeNewsWire • 12/16/20